Diabetologia, 0012-186X


View graph of relations

Related Publications
  1. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

    Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A. & Mayer, G., Jul-2019, In : Diabetologia. 62, 7, p. 1154-1166 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Blood Mg2+ is more closely associated with hyperglycaemia than with hypertriacylglycerolaemia: the PREVEND study

    van Dijk, P. R., Schutten, J. C., Jeyarajah, E. J., Kootstra-Ros, J. E., Connelly, M. A., Bakker, S. J. L. & Dullaart, R. P. F., Sep-2019, In : Diabetologia. 62, 9, p. 1732-1734 3 p.

    Research output: Contribution to journalLetterAcademicpeer-review

  3. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

    Matthews, D. R., Li, Q., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Desai, M., Hiatt, W. R., Nehler, M., Fabbrini, E., Kavalam, M., Lee, M. & Neal, B., Jun-2019, In : Diabetologia. 62, 6, p. 926-938 13 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. No availability, no uptake - exploring the reasons behind low uptake of insulin pump therapy in Irish adults with type 1 diabetes: findings from a national survey

    Gajewska, K. A., Sreenan, S., Bennett, K. E., Gajewski, J. & Biesma, R., Oct-2018, In : Diabetologia. 61, Suppl.1, p. S426-S426 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

View all (198) »

ID: 15741923